Zynerba Pharmaceuticals ( ZYNE ) had its Relative Strength ( RS ) Rating upgraded from 87 to 92 Monday.[ibd-display-video id=2102289 width=50 float=left autostart=true] IBD’s unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock’s price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating as they launch their largest runs.
See How IBD Helps You Make More Money In Stocks
Zynerba Pharmaceuticals is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could launch a new move.
The company reported 5% earnings growth in the latest quarterly report. Sales gains came in at -100%.
The company holds the No. 91 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Hutchison China MediTech ( HCM ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD’s Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.